Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 0404 • ACR Convergence 2020
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
Nadia Ahmad¹, Ayna Verdiyeva², Raashid Luqmani² and Shirish Dubey², ¹Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, ²Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
Abstract Number: 0626 • ACR Convergence 2020
Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients
Alisa Mueller¹, Tomoyoshi Tamura², Julia Jezmir³, Erin Penn¹, Gregory Keras⁴, Anthony Massaro⁵ and Edy Kim⁵, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Brigham and Women's Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, ³Brigham and Women’s Hospital, Department of Medicine, Boston, MA, ⁴Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA
Background/Purpose: During the course of hospitalization, it is often unclear which COVID-19 patients will progress from non-critical to critical illness. Timely identification of these patients…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 0828 • ACR Convergence 2020
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Stanley B Cohen¹, Yi-Hsing Chen², Naonobu Sugiyama³, Jose L Rivas⁴, Annette Diehl⁵, Tatjana Lukic⁶, Jerome Paulissen⁷, Haiyun Fan⁵, Tomohiro Hirose³ and Edward C Keystone⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Syneos Health, Morrisville, NC, ⁸Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: ORAL Shift (NCT02831855) was a 48-week Phase 3b/4 study, which demonstrated sustained efficacy/safety of tofacitinib modified release 11 mg once daily (QD) following MTX…
Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
John Tesser¹, Grace Wright², Vibeke Strand³, Jeffrey Kaine⁴, Karina Maslova⁵, Gregory St John⁶, Kerri Ford⁵, Amy Praestgaard⁵ and Ernest Choy⁷, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Association of Women in Rheumatology, New York, NY, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Independent Rheumatology Consultant, Sapphire, NC, ⁵Sanofi, Cambridge, MA, ⁶Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…
Abstract Number: 1232 • ACR Convergence 2020
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
Andrea Rubbert Roth¹, Daniel Furst*², Stefano Fiore³, Amy Praestgaard⁴, Vivian Bykerk⁵, Clifton Bingham III⁶ and Christina Charles-Schoeman⁷, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
Abstract Number: 1358 • ACR Convergence 2020
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Atul Deodhar¹, Lianne Gensler², Stephen Hall³, Philip Robinson⁴, Bengt Hoepken⁵, Lars Bauer⁵, Thomas Kumke⁵ and Walter Maksymowych⁶, ¹Oregon Health & Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Cabrini Medical Centre, Monash University and Emeritus Research, Malvern, Victoria, Australia, ⁴University of Queensland, Herston, Queensland, Australia, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA)…
Abstract Number: 1366 • ACR Convergence 2020
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
Juergen Braun¹, Ricardo Blanco², Helena Marzo-Ortega³, Lianne Gensler⁴, Filip Van den Bosch⁵, Hideto Kameda⁶, Denis Poddubnyy⁷, Marleen van de Sande⁸, Anna Wiksten⁹, Brian Porter¹⁰, Santiago Moreno⁹, Abhijit Shete⁹, Hanno Richards⁹, Sibylle Haemmerle⁹ and Atul Deodhar¹¹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴University of California San Francisco, San Francisco, CA, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Toho University, Tokyo, Japan, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Oregon Health & Science University, Portland, OR
Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…
Abstract Number: 340 • 2019 ACR/ARP Annual Meeting
Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels
Naomi Schlesinger¹, Kyle Jablonski ², Peter Harb ³, Caitlin Henry ³, Emily Schwarz ³, Ifeoma Okafor ³, Wael Jarjour ⁴ and Nicholas Young ⁵, ¹Rutgers Health- RWJ Medical School, New Brunswick, NJ, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ³Ohio State College of Medicine, Columbus, ⁴Ohio State College of Medicine, Columbus, OH, ⁵The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH
Background/Purpose: Regular exercise programs were previously thought to be inappropriate in patients with rheumatic diseases because of the potential to exacerbate inflammation. However, while recent paradigm-shifting…
Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Christine Xu¹, Patrick Nolain ², Qiang Lu ³, Anne Paccaly ⁴, Melitza Iglesias-Rodriguez ⁵, Gregory St John ⁶, Chad Nivens ⁴, Rafael Maldonado ⁷, Tomonori Ishii ⁸, Ernest Choy ⁹ and Vanaja Kanamaluru ³, ¹Sanofi, Bridgewater, NJ, ²Sanofi-Aventis, Montpellier, France, ³Sanofi, Bridgewater, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Pompeu Fabra University, Barcelona, Spain, ⁸Tohoku University Hospital, Sendai, Japan, ⁹Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
Abstract Number: 1509 • 2019 ACR/ARP Annual Meeting
Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Atul Deodhar¹, Philip Mease ², Paula Machado ³, Xiangyi Meng ³, Vibeke Strand ⁴ and Marina Magrey ⁵, ¹Oregon Health & Science University, Portland, OR, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁵Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS), a chronic inflammatory disease involving the sacroiliac joints and spine, is associated with pain, stiffness, disability, and reduced quality of life.1,2…
Abstract Number: 2458 • 2019 ACR/ARP Annual Meeting
Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation
Carina Borst¹, Farideh Alasti ² and Daniel Aletaha ³, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) belongs to the group of the spondylarthropathies. It is associated with psoriasis and typically seronegative for autoantibodies. PsA disease activity can…
Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Oliver Hendricks¹, Stavros Chrysidis², Jens Gerwien³, Chadi Saifan³, Francesco de Leonardis³, Pedro Lopez-Romero³, Jinglin Zhong⁴, Kevin Winthrop⁵ and Josef S. Smolen⁶, ¹King Chr.Xs Rheumatology Hospital, Graasten, Denmark, ²Rheumatology Department Sydvestjysk Sygehus, Esbjerg, Denmark, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Rockville, MD, ⁵Oregon Health Sciences University, Portland, OR, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…
Abstract Number: 2619 • 2018 ACR/ARHP Annual Meeting
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Lesley Jackson¹, Jeffry Bieber^1,2 and R. Eric Heidel³, ¹Graduate School of Medicine, Department of Internal Medicine, University of Tennessee Medical Center Knoxville, Knoxville, TN, ²UT Rheumatology, Knoxville, TN, ³Graduate School of Medicine, Division of Biostatistics, and Department of Surgery, University of Tennessee Medical Center Knoxville, Knoxville, TN
Background/Purpose: It is well established that psoriatic arthritis is associated with increased cardiovascular disease risk. The use of statins may impart anti-inflammatory effects, possibly through…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].